A 'family spat' spills out in public, as scientists debate effort to build a human genome
By Andrew Joseph,
STAT News
| 06. 04. 2016
Untitled Document
NEW YORK — Harvard Medical School’s George Church and Stanford University’s Drew Endy are top scientists who have expanded the boundaries of biology with their pioneering discoveries. They have written papers together and even cofounded a synthetic biology company.
But over the past month, they have been cast as the opposing spokesmen in the debate over whether scientists should try to build human and other genomes from scratch, a project that could transform our understanding of the basic building blocks of life but that is fraught with ethical issues.
...
But the project raises thorny ethical questions. Although it’s not a goal of the project, in theory, brewing up a complete human genome could lead to the formation of an actual person, sans parents. The effort, in other words, picks at the most fundamental question of our identity: What does it mean to be human?
Continue reading on STAT News
Image via Wikimedia
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
